The processing of amyloid precursor protein (APP) is a key event in the pathogenesis of Alzheimer's disease. As certain cleavage pathways tend to occur in particular subcellular compartments, the processing of APP is greatly influenced by factors that regulate its trafficking. Here we report that SCG10 directly interacts with the KFFEQ motif of the APP intracellular domain and promotes the non-amyloidogenic processing of the APP. Knockdown of SCG10 led to decreases in a cleavage products, sAPPa and CTFa, while increases of both Ab1-40 and Ab1-42. Elevation of SCG10 induced APP accumulation in post-Golgi vesicles and on the cell surface by facilitating its secretory pathway. In addition, the APP processing was dependent on the palmitoylation-mediated membraneanchoring of SCG10. Furthermore, elevation of SCG10 reduced Ab accumulation and amyloid plaque formation in the hippocampus of APPswe/PS1dE9 mice. Taken together, these results show that SCG10 has a potential role in preventing and treating Alzheimer's disease.
INTRODUCTION
Alzheimer's disease (AD), one of the most devastating neurodegenerative diseases, is characterized by two major pathological hallmarks, intracellular neurofibrillary tangles and extracellular senile plaques, mainly composed of b-amyloid peptide (Ab), a proteolytic product of amyloid precursor protein (APP) (1, 2) . APP is a type I transmembrane protein (3), with a large NH 2 -terminal extracellular domain and a small intracellular COOHterminal tail. Proteolytic enzymes process APP through two pathways. Initially processed by b-secretases (4, 5) , APP is cleaved into a large soluble fragment, sAPPb, and a membrane-retained C-terminal fragment, named CTFb (6); the latter can be further cleaved by the g-secretase complex and release Ab as well as the APP intracellular domain (AICD). Alternatively, a-secretases cleave inside the Ab sequence (7), producing sAPPa and CTFa; sAPPa is secreted, while CTFa generates the p3 peptide and the AICD after processing by the g-secretase complex (8) . The major species of Ab are Ab1 -42 and Ab1 -40, with the former more toxic and more prone to aggregation (9) . Several proteins interact with the conserved YENPTY motif of the AICD and regulate APP trafficking and processing (10) , including adaptor proteins like X11/Mint in vesicle docking and exocytosis (11) , Fe65 in cellular motility and transcription regulation (12) and c-Jun N-terminal kinase (JNK)-interacting protein for fast axonal transport (13) .
The stathmin family contains multi-tasking proteins identified in cellular signal transduction and microtubule dynamics regulation (14) (15) (16) . All members share a stathmin-like domain, which consists of a 'phosphorylation-regulatory' domain and a coiledcoil 'interaction' domain (17, 18) . SCG10, a member of stathmin family specifically expressed in neurons, possesses all four wellconserved stathmin phosphorylation sites (19) , and an NH 2 -terminal domain that contributes to membrane anchoring with the palmitoylation of two cysteine residues (20, 21) . It exists in intracellular membrane compartments like the Golgi apparatus and vesicles and is highly enriched in structures like growth † These authors contributed equally to this work.
cones (22, 23) . Consistent with its membrane localization, SCG10 has also been suggested to play a role in protein transport and secretion (24, 25) . Site-directed mutagenesis of two cysteine sites in the NH 2 -terminal domain shows a partial loss of membrane binding as well as prevention of growth cone transport (20, 23) .
SCG10 is a developmentally regulated neuronal growthassociated protein, expressed at high levels during neurogenesis (26, 27) , and at low but detectable levels in adulthood (27, 28) . APP expression is also induced progressively during neuronal differentiation and synaptogenesis (29, 30) . Moreover, taking intracellular localization into account, SCG10 anchors to membrane by its NH 2 -terminal domain (20) , while APP is a type I transmembrane protein. It is well known that a small portion of APP is transported to the plasma membrane by the constitutive secretory pathway after nascent APP reaches the Golgi apparatus, while the majority resides in the Golgi localization apparatus (31) . Thus, both APP and SCG10 show a typical Golgi pattern and vesicular structures (20, (32) (33) (34) . However, whether the intracellular transport of APP from the Golgi apparatus to the cell surface is regulated by some mediators remains to be elucidated. Here, we provide evidence to show that SCG10, a binding partner of APP, regulates APP trafficking in the secretory pathway, and to shed light on the function of SCG10 in APP processing.
RESULTS

SCG10 directly interacts with APP in Golgi apparatus
To investigate the spatial relationship between SCG10 and APP, we performed a subcellular fractionation assay of postnatal day 2 (P2) mouse brain. SCG10 and APP co-distributed in the light fraction enriched with the trans-Golgi network (TGN) vesicle marker syntaxin-6 and partially co-sedimented in the fractions with the cis-Golgi marker GM130 (Supplementary Material, Fig. S1A and B). To explore whether SCG10 interacts with APP, we performed GST pull-down assays in brain-derived neuro2A (N2a) cells stably expressing human APP695 (APPwt/ N2a). APP was specifically retained on the SCG10-GST-coated beads (Fig. 1A) . Also, a strong interaction between purified SCG10-GST and His 6 -tagged recombinant AICD49 (647 -695aa for APP695) was detected in vitro (Fig. 1B) . Furthermore, the results of immunoprecipitation also showed the interaction between APP and SCG10 by anti-GFP antibody in HEK293T cells epitopically expressing APP and SCG10-GFP (Fig. 1C) , and by anti-APP antibodies in P2 mouse brain extracts (Fig. 1D) . These results indicate that APP, mediated by its AICD, binds to SCG10 and forms a complex in vitro and in vivo.
Based on nuclear magnetic resonance spectroscopy studies, AICD has been structurally divided into distinct regions (35, 36) . To map the exact amino acid sequence on AICD, which mediates the interaction with SCG10, we constructed a series of truncated mutants. Yeast two-hybrid assays showed that deletion of a motif spanning APP 688-695 (KFFEQMQN) abolished their association (Fig. 1E) . Anti-GFP antibodies were immunoprecipitated with APP1-692 in SCG10-GFP/APP1-692-expressing HEK293T cells to a much greater extent than with APP1-687 in SCG10-GFP/APP1-687 expressing HEK293T cells ( Fig. 1F and G) . Thus, the sequence KFFEQ 692 of AICD plays a pivotal role in the interaction of APP with SCG10.
To investigate whether SCG10 and APP co-localize in cells, we co-transfected SCG10-GFP/-RFP and APP-RFP/-GFP to HeLa and N2a cells, and the results showed that these two fusion proteins partially moved together and overlaid with each other in the perinuclear region as well as in punctuate structures in the cytoplasm of the cells ( Fig. 1H ; Supplementary Material, Fig. S1C -E, and Movie S1), a pattern similar to their native distribution when separately immunostained (23, 37) . Consistent with our subcellular fractionation assay results (Supplementary Material, Fig. S1A and B), they showed a high degree of co-localization with both cis-and trans-Golgi apparatus (GM130 and TGN46 or syntaxin-6 staining, respectively), whereas SCG10 fluorescence was hardly detectable in the regions stained by EEA1, an early endosome marker ( Fig. 1H ; Supplementary Material, Fig. S1D and E). These suggest that the interaction of SCG10 with APP is more likely to occur in the Golgi apparatus rather than in the endosomes. Also, SCG10-RFP and APP-GFP co-localized in vesicle-like dots and co-transported along axons in cultured hippocampal neurons (Supplementary Material, Fig. S2A , B, and Movie S2).
To visualize the direct interaction between SCG10 and APP, we performed fluorescence resonance energy transfer (FRET) assay (38) . The N2a cells were co-transfected with SCG10-CFP (donor) and APP-YFP (acceptor) (Fig. 1I) . When the fluorescence of the acceptor was bleached, the intensity of donor fluorescence was enhanced (Fig. 1I, ROI1 ) compared with the value before bleaching. APP-YFP and SCG10-CFP showed 12% FRET efficiency (Ef) in the bleached zone than the control efficiency (Cf) of 1% in the unbleached zone ( Fig. 1J and K) . This confirms that SCG10 binds to APP in a direct manner in vivo.
Depletion of SCG10 affects Ab generation and APP processing
Based on the results that APP co-localized with SCG10 in TGN, which has been identified as a major compartment of Ab production (37), we reasoned that SCG10 may effect on APP processing and Ab generation. We effectively knocked down SCG10 using shRNA constructs in N2a cells or SCG10-overexpressed HEK293T cells (Supplementary Material, Fig. S3A and B) . In shSCG10-treated APPwt/N2a cells, we found that the levels of two major species of Ab were significantly increased, Ab1-40 by 25% and Ab1-42 by 30% ( Fig. 2A and B) . These phenotypes were completely rescued by the expression of a shRNA-resistant SCG10 construct ( Fig. 2A and B) . We then examined the a-, b-and g-secretases in HEK293T cell extracts. However, the results showed that none of their activities was significantly altered by the overexpression of SCG10 (Supplementary Material, Fig. S3C ). We further quantified the products of a-and b-secretases cleavage, a large a-and b-fragment ectodomain of APP (sAPPa and sAPPb) and the corresponding small cytoplasmic fragments, CTFa and CTFb. In the conditioned medium from APPwt/N2a cells, knockdown of SCG10 significantly decreased the sAPPa level (50%) (Fig. 2C and D) and resulted in a dramatic reduction in the level of CTFa (Fig. 2C) , while the production of sAPPb and CTFb did not change significantly ( Fig. 2C and E) . With the ectopic expression of the rescue construct of SCG10, the effects of SCG10 knockdown on sAPPa and CTFa were reversed ( Fig. 2C and D) . To further investigate the function of SCG10 in APP processing in neuronal cells, we overexpressed SCG10 and APP in cultured mouse cortical neurons by lentivirus. SCG10 resulted in an increase of sAPPa ( 63%) (Fig. 2F and G) , as well as decreased Ab1-40 ( 14%) (Fig. 2I) . But the level of sAPPb ( Fig. 2F and H) and Ab1-42 ( Fig. 2J ) remained largely unaffected. These results indicate that SCG10 promotes APP nonamyloidogenic processing in neuronal cells.
In order to test whether SCG10 affects APP processing through their direct interaction, we measured the levels of the proteolytic products of the C-terminal-truncated mutants APP1-687 (lacking the SCG10-binding site), APP1-692 (with the SCG10-binding site) and wild-type APP (APPwt), with or without SCG10, in HEK293 cells. Substantial increases of sAPPa and sAPPb were found in SCG10-GFP and APPwt cotransfected cells, compared with the case of GFP controls ( Fig. 2K-M) . Also, Ab1 -40 secretion was decreased by 21% and Ab1-42 by 25% ( Fig. 2N and O), which were consistent with the knockdown results in APPwt/N2a cells ( Fig. 2A and B) . The APP1-692 mutant had a phenotype similar to APPwt (Fig. 2K-O ). In line with the results that APP1-687 was unable to interact with SCG10, its processing was rarely affected by SCG10-GFP overexpression ( Fig. 2K-O) . Altogether, these data show that SCG10 promotes the a-processing of APP through binding to APP KFFEQ motif.
SCG10 affects subcellular localization of APP
The processing of APP not only depends on the activities of secretases, it is also related to cell localization of APP and its trafficking through subcellular compartments (39, 40) . Previous studies have indicated that a-cleavage of APP occurs primarily at or near the plasma membrane (7, 41) . We carefully compared the subcellular distribution of APP in SCG10-overexpressing and control N2a cells. APP was mostly located in the perinuclear compartment and co-stained with the Golgi markers, syntaxin-6 and GM130, in RFP-expressing control N2a cells (Fig. 3A) . Upon SCG10-RFP overexpression, besides those remaining overlaid with Golgi markers, a subpopulation of APP proteins was shifted into post-Golgi vesicle-like dots co-localized with SCG10 ( Fig. 3A, arrowheads) . And time-lapse data showed that APP-GFP and SCG10-RFP were moving together in HeLa cells (Supplementary Material, Fig. S1C and Movie S1). Of note, SCG10 caused no evident changes in either the staining intensity or distribution of each marker protein (Fig. 3A) . As SCG10 increased APP in the post-Golgi vesicle-like dots, it was reasonable to speculate that SCG10 might influence the presence of APP on the cell surface. N2a cells were transfected with SP-GFP -APP, a construct with a GFP tag inserted between the signal peptide (SP) and the rest of the APP sequence (Supplementary Material, Fig. S4A ), and the surface staining intensity of GFP (Fig. 3B ) after silencing endogenous SCG10 was quantified. The ratio of surface-to-total APP was calculated by dividing the GFP antibody staining (surface APP) by the intensity of GFP fluorescence (total APP). The results showed a 55% decrease in surface APP upon SCG10 knockdown (Fig. 3C) . To proceed further, we performed cell surface biotinylation studies to determine the changes of surface APP upon SCG10 overexpression or depletion (Fig. 3D) . Twenty-four hours after SCG10-FLAG transfection, APPswe/HEK293 cells showed about a doubling of surface APP, compared with the SCG10-depletion background (Fig. 3E) . When the SCG10-FLAG and shSCG10 were co-expressed, ectopic SCG10 was eliminated, and knockdown cells exhibited a 40% reduction of surface APP compared with those in the presence of exogenous SCG10 and pSUPER vector control ( Fig. 3D and E) . These results show that SCG10 increases the distribution of APP on the cell surface.
SCG10 promotes APP trafficking from Golgi apparatus to the cell surface
To gain insight into the mechanism of altered distribution of APP by SCG10, we investigated the effects of SCG10 on APP trafficking in the secretory pathway. N2a cells were transfected with SP-HA-APP (Supplementary Material, Fig. S4A ) and treated with brefeldin A (BFA). This treatment resulted in APP re-location throughout the cytoplasm (Fig. 4A, BFA) , consistent with the reports that BFA completely abolishes APP transport from the ER to the Golgi apparatus and thus blocks APP cell surface processing (34, 42) . In SCG10-overexpressing N2a cells, APP exhibited a similar BFA-sensitive diffuse pattern (Fig. 4A, BFA) . After BFA was washed out for 30 min, a portion of the APP regained the Golgi localization, while the cell surface APP recovered 2 h after washing (Fig. 4A) . Compared with the control cells, SCG10 overexpression caused a faster enrichment of APP on the cell surface, with 50% more surface staining at 2 h after BFA removal (Fig. 4B) . To rule out the possibility that SCG10 promotes the accumulation of APP on the cell surface by affecting its endocytosis, we also assessed the dynamics of APP internalization in N2a cells and found no significant effects of SCG10 on APP endocytosis (Supplementary Material, Fig. S5) . Furthermore, the overexpression of SCG10 in primary cultured hippocampal neurons increased APP signals in axons (Supplementary Material, Fig. S4B and C) and facilitated the axonal transport of APP (Supplementary Material, Fig. S4B and D, and Movie S3). Collectively, these results suggest that SCG10 facilitates the routing of APP from the Golgi apparatus to the cell surface.
Palmitoylation of SCG10 is required for regulation of APP processing
A detailed examination of interaction domains between AICD and SCG10 by yeast two-hybrid assay revealed that the phosphorylation-regulation domain of amino acids 35 -110 on SCG10 defined the minimum requirement for AICD binding (Fig. 5A) . In this region, phosphorylation of Ser-50, Ser-62, Ser-73 and Ser-97 reduces its microtubule-destabilizing activity (19, 32, 43) . The pseudo-phosphorylated mutant SCG10-S50,62, 73,97D has no effect on microtubules, whereas the nonphosphorylatable mutant SCG10-S50,62,73,97A and wild-type SCG10 depolymerize microtubules (19) (Supplementary Material, Fig. S6 ). So we asked whether the phosphorylation status regulated the interaction of SCG10 with APP as well as its effect on APP processing. Fluorescence microscopy showed that no significant difference in the extent of co-localization with APP among wild-type SCG10, SCG10-S50,62,73,97A and SCG10-S50,62,73,97D mutants (Fig. 5B) ; co-immunoprecipitation results confirmed the interaction of APP with SCG10wt and also with the S50,62,73,97A and S50,62,73,97D mutants (Fig. 5C ). When different SCG10 constructs were separately overexpressed in APPswe/HEK293 stable cells, the analysis of their conditioned medium nevertheless revealed minor differences in Ab levels. Compared with SCG10wt, SCG10-S50,62,73,97D produced comparable amounts of sAPPa and Ab, while more Ab1 -40 was produced with SCG10-S50, 62,73,97A overexpression ( Fig. 5D -H) .
Although GST pull-down results indicated that SCG10 bound to the AICD directly in vitro (Fig. 1B) , membrane attachment of SCG10 may strengthen its interaction with APP, a bona fide integral membrane protein, in vivo. As the palmitoylation of two cysteines (Cys22 and Cys24) in the NH 2 -terminal domain of SCG10 contributes greatly to its membrane association (20) , we removed this modification by replacing both cysteine residues with alanine residues (SCG10-C22,24A) and further examined the effects of this mutant. SCG10-C22,24A lost Golgi apparatus localization and exhibited partial if not complete cytoplasmic localization (Fig. 5B) , as reported in COS-7 cells (20) . The double fluorescence results of APP-GFP and SCG10-C22,24A-RFP showed no TGN co-localization ( Fig. 5B; and Supplementary Material, Fig. S6 ). Less APP was immunoprecipitated with SCG10-C22,24A than with SCG10wt (Fig. 5C) . Furthermore, the production of sAPPa and Ab species in the conditioned medium from APPswe/ HEK293 stable cells was less affected by SCG10-C22,24A than SCG10wt (Fig. 5D-H) . Taken together, these data show that the regulatory effect of SCG10 on APP processing relies heavily on the palmitoylation-dependent membrane association of SCG10, rather than the phosphorylation status of the serine residues in the phosphorylation-regulation domain.
SCG10 reduced Ab plaque formation in vivo
Finally, we investigated whether SCG10 mediates Ab deposition in the hippocampus of APPswe/PS1dE9 transgenic mice, an AD model harboring APP Swedish mutations (APP695 K595N/M596L) and a human PS1dE9 mutation (deletion of exon 9) at a single locus (44) . These mice exhibited abnormal spatial reference memory and impaired coordination by 12 months, and Ab deposits were observed in the hippocampus and cortex by 6 months of age (44) . We used the lentiviral system to overexpress SCG10 in the hippocampus of APPswe/ PS1dE9 mice. Lentivirus containing SCG10-IRES-GFP successfully overexpressed SCG10 and GFP in infected HEK293T cells (Supplementary Material, Fig. S7 ). Then, we injected SCG10-IRES-GFP lentivirus into the right and IRES-GFP control lentivirus into the left hippocampus of 4-month-old female APPswe/PS1dE9 mice. After 2 months, we examined the Ab deposition in the GFP-expressing hippocampal coronal sections by immunostaining the Ab plaques with the monoclonal antibody 6E10 and found a lower Ab plaque density (percentage area of plaque, P , 0.05) in the hippocampus overexpressing SCG10 compared with control ( Fig. 6A and B) . However, in cortex where no lentivirus was injected, the densities of amyloid plaques were comparable on both sides ( Fig. 6A and C) . These results indicate that SCG10 plays a role in Ab deposition and can reduce amyloid plaques formation in vivo.
DISCUSSION
APP is synthesized in endoplasmic reticulum and transported to the Golgi apparatus. At steady state, the majority of APP localizes to the Golgi apparatus, while a small fraction of APP is transported to plasma membrane through constitutive secretory pathway. Uncleaved APP is quickly internalized from plasma membrane to early endosomes and subsequently sorted to late endosomes and lysosomes, TGN or recycled back to plasma membrane (31) . Several sorting signals in AICD have been reported to be required for its sorting and intracellular trafficking, including YENPTY motif for internalization (45) (46) (47) and YKFFE motif for the Golgi apparatus to endosomes transportation (48) . Here we show that APP directly interacts and co-localizes with SCG10 in the TGN, and the KFFEQ motif of APP is crucial for its post-Golgi sorting and trafficking. Structural studies revealed that a nascent helix structure exhibited by this KFFEQ region provides a relatively flexible folding feature suitable for protein binding (36) . SCG10 may recognize such a unique structural fold and directly binds to this region with induced conformational change. The KFFEQ motif-mediated interaction with SCG10 may help sorting APP into a discrete membrane domain and ultimately facilitating the packaging of APP into post-Golgi transport vesicles for its secretory trafficking (see model in Fig. 6D ). Our results are thus consistent with the report that SCG10 promotes chromogranin A secretion through interaction (25) . APP is transported by directly binding to kinesin-1 or indirectly through JIP-1b along microtubules in axons during its postGolgi transport (13, 49, 50) . It is reported recently that calsyntenin-1, a ligand for kinesin-1 light chains, mediates Golgi exit and axonal transport of APP in a kinesin-1-dependent manner (51 -53) . Our data in neurons reveal that SCG10 increases the number of APP-containing vesicles in axons and facilitates APP fast axonal transport, consistent with the model that SCG10 directly promotes APP Golgi exit and transport to cell surface. At this stage, we cannot completely exclude the possibility that SCG10 may also promote APP axonal transport through indirect pathway, as previous reports showed that SCG10 could regulate microtubule dynamics, and may in turn affect axonal transport (24, 43, 54) .
The proteolytic processing of APP is largely regulated by its subcellular localization and trafficking. Three APP secretases with distinct subcellular distribution are involved in the sequential proteolysis of APP in a specific set of subcellular compartments along two major pathways (37, 40, 55) . b-secretases, responsible for the amyloidogenic pathway, tend to be active in the environment of the TGN or endosomal -lysosomal compartments (40) , while a-secretases are primarily found on the cell surface (7, 39) , to promote the non-amyloidogenic pathway. Our results show that SCG10 does not affect APP in the endocytosis pathway, but facilitates APP transport in the secretory pathway, and thus increases the surface localization of APP. Therefore, the role of SCG10 fits the pathway where the non-amyloidogenic processing occurs (see model in Fig. 6D ) and provides a mechanical explanation for how a-processing of APP could be facilitated. In addition, it was found that b-processing product CTFb in the amyloidogenic pathway could be processed by a-secretases in the non-amyloidogenic pathway (56) . Thus, the products of amyloidogenic and nonamyloidogenic pathways might not always inversely correlate with each other as originally thought (57, 58) . Indeed, we find that in APPswe/HEK293 cells, overexpression of SCG10 increases both the levels of sAPPa and sAPPb while decreases the level of Ab. In contrast, however, in primary cortical neurons, overexpression of SCG10 did not increase the level of sAPPb, which reminds us that cell-type-specific mechanisms appear to exist in regulating the APP proteolytic processing.
Two major Ab species, Ab40 and Ab42, are thought to mediate the AD pathogenesis, which are generated by sequential cleavage of b-and g-secretases. To reduce Ab burden, the current therapeutic strategy to treat AD has been heavily focused on Ab immunization and the inhibitors of Ab-secretases (59, 60) . Our data show that overexpression of SCG10 facilitates the a-processing of APP and decreases the level of Ab, while the palmitoylation of two cysteine residues within the NH 2 -terminal domain of SCG10 is required for its function. Moreover, overexpressing SCG10 in the hippocampus of AD mouse model has significantly reduced Ab deposition in vivo, suggesting that SCG10 might serve as a modulator for b amyloid production. Consistently, abnormal SCG10 localization occurs in AD-affected brain regions such as the hippocampus and cerebral cortex (61) . Together these observations provide a new regulatory paradigm for APP processing in normal and AD brains. Thus, it is of prime interest to investigate the mechanisms underlying modulation of SCG10-mediated APP sorting and trafficking, which might serve as new therapeutic targets for AD prevention and treatment.
MATERIALS AND METHODS
Cell culture, immunofluorescence and antibodies
Neuro2A (N2a) cells stably expressing human APP695 (APPwt/ N2a cells) and HEK293 cells stably expressing human APP695 Swedish mutant (APPswe/HEK293 cells) were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal bovine serum and maintained in medium containing 250 mg ml 21 G418. Transient transfections were carried out using jetPEI (Polyplus-transfection). Confocal images were taken with a 100× oil-immersion lens (Zeiss LSM 710 NLO&DuoScan). Co-localization efficiency was analyzed by Imaris (Bitplane). Mouse anti-HA (clone HA-7), anti-GAPDH (clone GAPDH-71.1) and anti-FLAG (clone M2) antibodies were from Sigma. Mouse anti-GFP antibody (clone RQ-2) was from MBL. Mouse anti-GM130 (clone 35) and mouse anti-EEA1 (clone 14/EEA1) were from BD Transduction Laboratories. Mouse anti-syntaxin 6 (clone 3D10), rabbit polyclonal anti-TGN46 and rabbit polyclonal anti-EEA1 were from Abcam. Mouse anti-SCG10 (clone 2-RE19) was from Santa Cruz Biotechnology. Rabbit anti-APP (clone Y188) was from Epitomics, mouse anti-APP (clone 22C11) from Millipore and mouse anti-APP (clone 4G8) from Covance. Mouse antihuman sAPPa (clone 2B3) and rabbit polyclonal antibody against sAPPb were from IBL. Secondary anti-rabbit and antimouse IgG antibodies conjugated to horseradish peroxidase (HRP) for immunoblotting were from Jackson Labs; and secondary anti-mouse, anti-rat and anti-rabbit antibodies for immunofluorescence analysis were from Molecular Probes (Alexa Fluor series).
cDNA cloning, expression and GST pull-down analysis
For expression of SCG10, the cDNA was amplified from mouse brain by RT-PCR and cloned into pGEX4T-1 (Amersham Biosciences); AICD was amplified from APP695 cDNA and cloned into pET-28a (Novagen). AICD was purified by affinity resin chromatography (BD Bioscience Clontech); GST and GST-SCG10 were purified following the manufacturer's instructions. GST pull-down assay was performed by suspending recombinant proteins in buffer H (50 mM Hepes, pH 7.4, 10% glycerol, 150 mM NaCl, 1.5 mM MgCl 2 , 1% Triton X-100 and 1 mM EGTA) and incubating them with the loaded beads for 2 h at 48C. After washing three times with buffer H, the eluted proteins were analyzed with 12% SDS -PAGE. For GST pull-down assay, GST or GST fusion protein was incubated with APPwt/N2a cell lysates in buffer H, and similar procedures were performed.
Co-immunoprecipitation assay and western blotting
P2 mouse brains were pre-washed with PBS and homogenized on ice in a Dounce homogenizer. After centrifugation at 1400 g at 48C for 10 min, supernatant was collected and centrifuged again at 13 800 g for 10 min. The pellets were then homogenized in extraction buffer (20 mM Tris -HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 5 mM MgCl 2 , 1 mM DTT, 10% glycerol, 1% Nonidet P-40, 0.5% sodium deoxycholate and proteinase inhibitor mixture) with 10× passage through a 29-gauge needle. Cleared lysates were pre-mixed either with 3-5 mg of monoclonal antibody 4G8 or pre-immune IgG at 48C for 2 h. The immunocomplexes were incubated with protein A-Sepharose beads (Pharmacia) at 48C overnight. After extensive washes with extraction buffer, the bound proteins were collected with 2× SDS sample buffer and analyzed by SDS -PAGE and western blotting. For the co-immunoprecipitation assay using HEK293 T cells, the transfected cells were washed in PBS and lysed with ice-cold extraction buffer, and then immunoprecipitation was performed as described earlier. After gel electrophoresis, western blotting was carried out as described earlier (38) . Briefly, proteins were transferred to PVDF membrane (Millipore). After blocking in 5% low-fat milk in 1× TBST (0.2% Tween-20), the membrane was probed with primary antibodies and detected by HRP-conjugated secondary antibodies.
Silencing of SCG10 expression and rescue
To generate a shRNA vector against SCG10, we cloned the following oligonucleotides into pSUPER: forward, 5 
Analyses of APP processing
APPswe/HEK293 or APPwt/N2a cells were transfected as described earlier. For the detection of secreted sAPPs, serumfree culture medium was added to the cells after transfection, and the conditioned medium was collected for subsequent analysis by western blotting (sAPPa and sAPPb) or ELISA (Ab1 -40 and Ab1 -42). To measure full-length APP and CTFs, cells were lysed on ice after washing three times with PBS. The media and cell lysates were analyzed by SDS-PAGE on 8 or 12% Tris -Tricine gels and western blotting using specific antibodies. Densitometry of the bands from western blotting was determined using ImageJ (NIH). To quantify the Ab levels in the media, we performed sandwich ELISA assays using kits with capture and detection antibodies specific to Ab1-40 or Ab1 -42 (Invitrogen).
BFA treatment and immunostaining of cell surface and intracellular APP
To block APP transport at the ER-to-Golgi exit, N2a cells expressing the appropriate vectors were treated for 1 h with BFA (10 mg ml 21 ). BFA was removed by washing the cells three times with regular growth medium and incubating for 0, 30 or 120 min after BFA removal. To detect APP on the surface, the transfected N2a cells were directly incubated with anti-HA or anti-GFP antibody after fixation with pre-warmed 4% PFA containing 0.12 M sucrose, without permeabilization, followed by incubation with DyLight 649-labeled secondary antibody (KPL). After permeabilization, total intracellular APP was stained sequentially with anti-HA antibody and AlexaFluor 488-labeled secondary antibody.
Biotin labeling of cell surface proteins
Twenty-four or 72 h after transfection (depending on whether they were overexpression or shRNA experiments), APPswe/ HEK293 cells were washed with cold PBS followed by incubation with sulfo-NHS-SS-biotin (0.5 mg ml 21 , Pierce) for 1 h at 48C. The reaction was stopped by washing three times with quenching buffer (50 mM NH 4 Cl, 1 mM MgCl 2 and 0.1 mM CaCl 2 ) in PBS and three subsequent washes in PBS. Cells were then lysed and precipitated with streptavidin sepharose (GE) at 48C for 2 h. Biotinylated proteins in the precipitated fraction were subjected to western blotting analysis.
APPswe/PS1dE9 mice, intracerebral injection and immunostaining
APPswe/PS1dE9 transgenic mice were purchased from the Model Animal Research Center of Nanjing University and kept in a specific pathogen-free environment in the Peking University Laboratory Animal Center. These mice carry a chimeric APP with Swedish mutations and human PS1dE9 mutation at a single locus (44) . They were maintained as hemizygotes by breeding transgenic mice to wild-type siblings. All experiments were undertaken in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Committee of Animal Research in Peking University.
Injections were performed as reported (64) . Briefly, 4-month-old female APPswe/PS1dE9 mice were anesthetized with pentobarbital sodium and then fixed on a stereotaxic apparatus. One microliter of prepared lentivirus (1 × 10 6 transducing units) was injected into the hippocampus (from bregma: AP, 2.0 mm; ML, +1.5 mm; 2.0 mm below the skull surface) at a speed of 0.1 ml min
21
. SCG10-IRES-GFP lentivirus was injected into the right hippocampus and IRES-GFP lentivirus into the left. The syringe was left for another 10 min before withdrawal. Injected mice were then separately housed for 2 months and sacrificed for sectioning.
Cryostat coronal sections of brain were prepared using a cryomicrotome (CM1850, Leica) as previously reported (65) . Sections were cut at 20 mm and incubated with anti-GFP and anti-Ab (6E10) primary antibodies followed by Alexa Fluor 488-and 568-conjugated secondary antibodies. Images were captured using a confocal fluorescence microscope (Zeiss LSM 710 NLO&DuoScan) and analyzed with ImageJ (NIH). Four to five sections in every half brain were analyzed for the average area occupied by amyloid plaques.
